UBS Group’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $92M | Sell |
545,937
-675,099
| -55% | -$100M | 0.01% | 1184 |
|
|
2026
Q1 | $161M | Buy |
1,221,036
+237,508
| +24% | +$31.5M | 0.02% | 726 |
|
|
2025
Q4 | $139M | Buy |
983,528
+618,956
| +170% | +$89.7M | 0.02% | 777 |
|
|
2025
Q3 | $51.2M | Sell |
364,572
-237,553
| -39% | -$32.2M | 0.01% | 1601 |
|
|
2025
Q2 | $75.7M | Sell |
602,125
-183,376
| -23% | -$21M | 0.01% | 1170 |
|
|
2025
Q1 | $86.9M | Buy |
785,501
+366,073
| +87% | +$46.4M | 0.02% | 1018 |
|
|
2024
Q4 | $57.3M | Buy |
419,428
+59,859
| +17% | +$7.4M | 0.01% | 1336 |
|
|
2024
Q3 | $41.4M | Buy |
359,569
+42,642
| +13% | +$5.85M | 0.01% | 1285 |
|
|
2024
Q2 | $43.6M | Buy |
316,927
+81,301
| +35% | +$11.1M | 0.01% | 1124 |
|
|
2024
Q1 | $32.5M | Buy |
235,626
+91,732
| +64% | +$12.5M | 0.01% | 1343 |
|
|
2023
Q4 | $19M | Buy |
143,894
+9,655
| +7% | +$1.11M | 0.01% | 1620 |
|
|
2023
Q3 | $15.1M | Buy |
134,239
+10,938
| +9% | +$1.15M | 0.01% | 1682 |
|
|
2023
Q2 | $11.6M | Sell |
123,301
-1,325
| -1% | -$129K | ﹤0.01% | 1858 |
|
|
2023
Q1 | $12.6M | Sell |
124,626
-92,172
| -43% | -$9.59M | ﹤0.01% | 1726 |
|
|
2022
Q4 | $25.9M | Buy |
216,798
+64,678
| +43% | +$7.58M | 0.01% | 1234 |
|
|
2022
Q3 | $16.2M | Buy |
152,120
+68,323
| +82% | +$6.93M | 0.01% | 1421 |
|
|
2022
Q2 | $8.17M | Sell |
83,797
-141,449
| -63% | -$13.1M | ﹤0.01% | 1966 |
|
|
2022
Q1 | $21.1M | Sell |
225,246
-610
| -0.3% | -$51.7K | 0.01% | 1377 |
|
|
2021
Q4 | $19.2M | Buy |
225,856
+54,141
| +32% | +$4.98M | 0.01% | 1609 |
|
|
2021
Q3 | $16.5M | Buy |
171,715
+30,328
| +21% | +$2.86M | 0.01% | 1651 |
|
|
2021
Q2 | $13.8M | Buy |
141,387
+49,514
| +54% | +$4.75M | ﹤0.01% | 1781 |
|
|
2021
Q1 | $8.94M | Buy |
91,873
+76,245
| +488% | +$8M | ﹤0.01% | 2056 |
|
|
2020
Q4 | $1.5M | Sell |
15,628
-557
| -3% | -$53.8K | ﹤0.01% | 3661 |
|
|
2020
Q3 | $1.56M | Sell |
16,185
-43,031
| -73% | -$4.98M | ﹤0.01% | 3294 |
|
|
2020
Q2 | $7.22M | Buy |
59,216
+9,120
| +18% | +$1.01M | ﹤0.01% | 1769 |
|
|
2020
Q1 | $4.34M | Sell |
50,096
-24,952
| -33% | -$2.44M | ﹤0.01% | 2054 |
|
|
2019
Q4 | $8.07M | Sell |
75,048
-29,711
| -28% | -$3.11M | ﹤0.01% | 2147 |
|
|
2019
Q3 | $9.44M | Buy |
104,759
+73,000
| +230% | +$6.82M | ﹤0.01% | 1810 |
|
|
2019
Q2 | $2.68M | Sell |
31,759
-11,859
| -27% | -$974K | ﹤0.01% | 2887 |
|
|
2019
Q1 | $3.84M | Sell |
43,618
-104,174
| -70% | -$8.71M | ﹤0.01% | 2415 |
|
|
2018
Q4 | $10.6M | Buy |
147,792
+105,626
| +251% | +$10.1M | ﹤0.01% | 1529 |
|
|
2018
Q3 | $5.18M | Buy |
42,166
+31,256
| +286% | +$3.55M | ﹤0.01% | 2318 |
|
|
2018
Q2 | $1.07M | Sell |
10,910
-50,319
| -82% | -$4.5M | ﹤0.01% | 3730 |
|
|
2018
Q1 | $5.08M | Buy |
61,229
+37,618
| +159% | +$3.18M | ﹤0.01% | 2292 |
|
|
2017
Q4 | $1.83M | Buy |
23,611
+21
| +0.1% | +$1.43K | ﹤0.01% | 3267 |
|
|
2017
Q3 | $1.45M | Sell |
23,590
-10,962
| -32% | -$578K | ﹤0.01% | 3395 |
|
|
2017
Q2 | $1.59M | Sell |
34,552
-9,910
| -22% | -$481K | ﹤0.01% | 3209 |
|
|
2017
Q1 | $1.93M | Sell |
44,462
-212
| -0.5% | -$9.08K | ﹤0.01% | 2977 |
|
|
2016
Q4 | $1.73M | Sell |
44,674
-21,517
| -33% | -$974K | ﹤0.01% | 3048 |
|
|
2016
Q3 | $3.35M | Sell |
66,191
-79,423
| -55% | -$3.96M | ﹤0.01% | 2396 |
|
|
2016
Q2 | $6.62M | Buy |
145,614
+110,364
| +313% | +$5.08M | ﹤0.01% | 1711 |
|
|
2016
Q1 | $1.39M | Sell |
35,250
-19,270
| -35% | -$765K | ﹤0.01% | 2989 |
|
|
2015
Q4 | $3.08M | Buy |
54,520
+38,426
| +239% | +$1.95M | ﹤0.01% | 2398 |
|
|
2015
Q3 | $641K | Buy |
16,094
+59
| +0.4% | +$2.85K | ﹤0.01% | 3704 |
|
|
2015
Q2 | $766K | Buy |
16,035
+4,322
| +37% | +$183K | ﹤0.01% | 3771 |
|
|
2015
Q1 | $466K | Sell |
11,713
-13,447
| -53% | -$481K | ﹤0.01% | 4196 |
|
|
2014
Q4 | $562K | Buy |
+25,160
| New | +$477K | ﹤0.01% | 4092 |
|
Other funds holding NBIX
UBS Group's NBIX Position: Q2 2026 in Review
UBS Group reduced its Neurocrine Biosciences (NBIX) stake by 55% in Q2 2026, selling an estimated $100M and leaving 545,937 shares worth $92M. The position accounts for 0.01% of the portfolio, ranked #1184.
UBS Group first reported a position in NBIX in Q4 2014 and has held it in 47 quarters since. The position peaked at $161M in Q1 2026. 774 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- UBS Group held 545,937 shares of Neurocrine Biosciences worth $92M as of Q2 2026.
- UBS Group sold 675,099 Neurocrine Biosciences shares in Q2 2026, an estimated $100M.
- Neurocrine Biosciences made up 0.01% of UBS Group's portfolio in Q2 2026, its #1184 holding.
- UBS Group first reported a position in Neurocrine Biosciences in Q4 2014 and has held it in 47 quarters since.
- UBS Group's Neurocrine Biosciences position peaked at $161M in Q1 2026.
- 774 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.